Sirtris Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs for the treatment of diseases associated with aging, including metabolic diseases, such as type 2 diabetes. Its drug candidates are used to mimic beneficial health effects of calorie restriction by activating SIRT1, which is a member of sirtuins enzymes. The company is developing SRT501, a proprietary formulation of resveratrol; proprietary new chemical entities, which are the new activators of SIRT1; and small molecule modulators of other sirtuins and related pathways for drug development in various areas, including metabolic, cardiovascular, and neurological diseases, as well as cancer. Sirtris Pharmaceuticals, Inc. was founded in 2004 and is based in Cambridge, Massachusetts.